Letter to the Editor
Liquid Warfarin Formulation for Oral Anticoagulation of a Neonate with a Renal Vein Thrombosis
Article first published online: 16 JAN 2013
© 2013 The Authors. Journal of Paediatrics and Child Health © 2013 Paediatrics and Child Health Division (Royal Australasian College of Physicians)
Journal of Paediatrics and Child Health
Volume 49, Issue 1, pages E106–E107, January 2013
How to Cite
Williams, V., Pham, C., Suppiah, R. and Melville, A. (2013), Liquid Warfarin Formulation for Oral Anticoagulation of a Neonate with a Renal Vein Thrombosis. Journal of Paediatrics and Child Health, 49: E106–E107. doi: 10.1111/jpc.12059
- Issue published online: 16 JAN 2013
- Article first published online: 16 JAN 2013
9 June 2012
Anticoagulation in a neonate is problematic. Warfarin is avoided due to the vitamin-K-dependent factors already being reduced, the influence of formula being supplemented with vitamin K and the fact that breast milk has minimal vitamin K. Inconsistent feeding patterns may also complicate the issue.
A mother with a known risk factor of gestational diabetes gave birth to a baby with left-sided renal vein thrombosis extending 12 mm cranially into the inferior vena cava. The child showed no evidence of thrombophilia.
Initially, the treatment was enoxaparin (low-molecular-weight heparin) administered every 12 h. It was recognised that the therapy would need to extend to 3 months due to the extent of the clot and that twice daily enoxaparin injections may be an unnecessary burden. Indeed, a liquid warfarin formulation was prepared (1 mg/mL) (Table 1), which allowed for easy oral administration using a graduated dropper.
|Warfarin sodium (Coumadin) 5 mg tablets pulverised in sufficient distilled water to produce a smooth magma||80|
|Disodium hydrogen phosphate added and mixed well||4 g dissolved in 50 mL distilled water|
|Tragacanth mucilage – mixed well||80 mL|
|Sorbitol compound syrup – mixed well||100 mL|
|Compound hydroxybenzoate solution (Australian Pharmaceutical Formulary)||4 mL|
|Freshly distilled water to a final volume of||400 mL|
There were no apparent side effects using the liquid anticoagulant, and a reasonable degree of anticoagulation was achieved. The target international normalised ratio (INR) was determined at 2–3, monitored using a CoaguChek XS point-of-care machine (Roche Diagnostics GmbH, Mannheim, Germany). The child was given a loading dose of 1 mg, followed by 0.4 mg daily, with a final dose of 0.65 mg or as close as possible using the graduated dropper. The INR ranged from a minimum of 1.4 at initiation to 4.4, with an average INR of 1.9. The child had an average of 6.8 feeds per day, and during the 3 months, the child gained approximately 2.5 kg. The increasing weight did not appear to impact on the required amount of warfarin. Dosing was adjusted according to the INR levels obtained.
While variability was noted during the anticoagulation, it did not appear to be related to the number of feeds per day or to increasing weight. Although there was no discernible change in the daily feeding patterns, the quality of feeds cannot be determined and, perhaps, played a role in the INR variability. Preferably, the baby should stay with breastfeeds or bottle feeds and avoid a mixture due to the varying vitamin K intake.
The degree of anticoagulation achieved in this child was sufficient to stop any progression of the thrombus, and indeed, the thrombus regressed. While frequent monitoring was necessary to maintain a therapeutic INR, the number of interventions was far less than twice daily injections with enoxaparin. At 12 months of age, the child was well developed, with full renal function.